
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
ZG16 (zymogen granule protein 16) encodes a protein predicted to bind carbohydrates and peptidoglycan. It is associated with protein transport and is predicted to participate in defense responses to Gram-positive bacteria and in suppression of symbiont entry into the host. The protein is localized to the Golgi lumen and collagen-containing extracellular matrix.
Human normal colonic epithelial cells are represented by NCM460, a cell line derived from normal colonic mucosa rather than a malignant tumor. The cells are classified as human intestinal epithelial cells and are commonly used as a non-tumorigenic intestinal epithelial model.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_015174
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?